Dianthus Therapeutics(NASDAQ) DNTH

Dianthus Therapeutics, Inc. helps people with serious immune system problems. These drugs let patients treat themselves at home with simple injections. The company makes life easier for people with rare diseases.

Medicines for the Immune System

• Claseprubart: Monoclonal antibody designed to block C1s, a specific protein in the immune system. This treatment is for patients with muscle weakness diseases like generalized Myasthenia Gravis.
• DNTH212: Fusion protein that stops two different parts of the immune system from attacking the body. It targets conditions such as Sjögren’s Disease and Systemic Lupus Erythematosus.
• DNTH312: Next-generation medicine that combines two different treatment types into one molecule. It is designed to help larger groups of patients with complex autoimmune conditions.

Moving Toward Market Approval

• Initiated the Phase 3 EMERGE trial for claseprubart in June 2026 to treat generalized Myasthenia Gravis.
• Achieved a 75% response rate in the first part of the CAPTIVATE trial for a nerve disorder in June 2026.
• Completed enrollment for the Phase 2 MoMeNtum trial in August 2026 for patients with a rare nerve disease.
• Licensed DNTH212 from Nanjing Leads Biolabs Co., Ltd. in October 2025 to expand the medicine pipeline.
• Received Orphan Drug Designation for claseprubart to treat muscle weakness in May 2026.

Simple Treatment for Complex Diseases

Dianthus uses technology to make medicines last longer in the body. This allows patients to take their medicine less often through a self-administered injection pen.

Checking the Financial Facts

• Cash, cash equivalents, and investments totaled $1.2 billion as of June 30, 2026.
• Research and development expenses were $48.7 million for the three-month period ended June 30, 2026, up $22.4 million year over year.
• Net loss reached $91.0 million for the six-month period ended June 30, 2026.
• License revenue was $1.2 million for the six-month period ended June 30, 2026, down from $1.4 million in the same period of 2025.

Bottom Line

Dianthus has transitioned from early research to late-stage clinical trials with its lead medicine. The company is building a portfolio of treatments that target multiple parts of the immune system.